Skip to main content
Premium Trial:

Request an Annual Quote

Mingyuan Buying 70 Percent Stake in Chinese MDx Firm Shanghai Yuanqi for $55M

NEW YORK (GenomeWeb News) – Chinese biomedical testing firm Mingyuan Medicare Development announced that its wholly own subsidiary SHMY HealthDigit Biochips has entered into an agreement to purchase 70 percent of Shanghai Yuanqi for CNY354 million ($55 million).

SHMY will pay CNY225 million in cash and issue about 327 million shares of Mingyuan stock at HK$.478 per share, totaling CNY129 million, for the deal.

Shanghai Yuanqi was founded in January 2010 and develops molecular diagnostic kits for leukemia, lymphoma, and individualized cancer therapy, according to Mingyuan. It added that Shanghai Yuanqi has developed a DNA sequencing and testing method for the analysis of circulating tumor cells from peripheral blood of cancer patients that provides insight into gene mutations.

The method involves the integration of gene mutation information, gene profile analysis, and application of targeted therapies and can be used "to provide accurate and updated information of gene mutation for those terminal cancer patients who would not be able to provide any physical cancer tissue sample as they are not fit for surgery," Mingyuan said in a statement.

Shanghai Yuanqi has created a database of more than 4,000 cases of cancer patients, the first of its kind in China, Mingyuan said. During 2010, Shanghai Yuanqi posted CNY872,600 in revenues and a loss of CNY668,300.

Mingyuan is based in Hong Kong and its first product was the Protein Chip System for Multi-tumor Marker Detection, or C-12, according to its website. The chips are its most profitable product, and the company said that the purchase of Shanghai Yuanqi will allow it to "further strengthen its cancer-related testing kits from general cancer screening, which is offered by the C12 protein chips … to specific testing kits for various specific cancers, leukemia and lymphoma."

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.